The relationship of montreal cognitive assessment scores to framingham coronary and stroke risk scores

Myron Frederick Weiner, Linda Susan Hynan, Heidi Rossetti, Matthew Wesley Warren, Colin Munro Cullum

.

DOI: 10.4236/ojpsych.2011.12008                

Abstract

We examined the relationship between a brief cognitive screening measure and Framingham Coronary and Stroke Risk scores. We administered the Montreal Cognitive Assessment (MoCA) to participants in the Dallas Heart Study, a community-based multiethnic study investigating the development of atherosclerosis. The composition of the group was 50% African American, 36% Caucasian and 14% Hispanic. There were 765 subjects (mean age 51 years) who had both Coronary and Stroke Risk scores and an additional 144 subjects with only Coronary Risk scores available. There was a small significant inverse relationship between MoCA and Framingham Coronary and Stroke Risk scores. MoCA scores were influenced by education, but were not influenced by age or by the presence of one or more apoE4 alleles.

Keywords

Dementia; Montreal Cognitive Assessment; Cognition; Cardiovascular Risk

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Beeri, M.S., Ravona-Springer, R., Silverman, J.M. and Haroutunian, V. (2009) The effects of cardiovascular risk factors on cognitive compromise. Dialogues in Clinical Neuroscience, 11, 201-212.
[2]	Middleton, L.E., Barnes, D.E., Lui, L.Y. and Yaffe, K. (2010) Physical activity over the life course and its association with cognitive performance and impairment in old age. Journal of the American Geriatrics Society, 58, 1322-1326. doi:10.1111/j.1532-5415.2010.02903.x
[3]	Yaffe, K., Vittinghoff, E., Lindquist, K., et al. (2010) Posttraumatic stress disorder and risk of dementia among us veterans. Archives of General Psychiatry, 67, 608-613. doi:10.1001/archgenpsychiatry.2010.61
[4]	Tzourio, C., Dufouil, C., Ducimetiere, P. and Alperovitch, A. (1999) Cognitive decline in individuals with high blood pressure: A longitudinal study in the elderly. Eva study group. Epidemiology of vascular aging. Neurology, 53, 1948-1952.
[5]	Mielke, M. M., Rosenberg, P. B., Tschanz, J., et al. (2007) Vascular factors predict rate of progression in alzheimer disease. Neurology, 69, 1850-1858. doi:10.1212/01.wnl.0000279520.59792.fe
[6]	Solomon, A., Kareholt, I., Ngandu, T., et al. (2007) Serum cholesterol changes after midlife and late-life cognition: Twenty-one-year follow-up study. Neurology, 68, 751-756. doi:10.1212/01.wnl.0000256368.57375.b7
[7]	Yaffe, K., Barrett-Connor, E., Lin, F. and Grady, D. (2002) Serum lipoprotein levels, statin use, and cognitive function in older women. Archives of Neurology, 59, 378-384. doi:10.1001/archneur.59.3.378
[8]	Reitz, C., Luchsinger, J., Tang, M.X., Manly, J. and Mayeux, R. (2005) Impact of plasma lipids and time on memory performance in healthy elderly without dementia. Neurology, 64, 1378-1383. doi:10.1212/01.WNL.0000158274.31318.3C
[9]	Whitmer, R. A., Sidney, S., Selby, J., Johnston, S. C. and Yaffe, K. (2005) Midlife cardiovascular risk factors and risk of dementia in late life. Neurology, 64, 277-281. doi:10.1212/01.WNL.0000149519.47454.F2
[10]	Schnaider Beeri, M., Goldbourt, U., Silverman, J.M., et al. (2004) Diabetes mellitus in midlife and the risk of dementia three decades later. Neurology, 63, 1902-1907.
[11]	Yaffe, K., Kanaya, A., Lindquist, K., et al. (2004) The metabolic syndrome, inflammation, and risk of cognitive decline. Journal of the American Medical Association, 292, 2237-2242. doi:10.1001/jama.292.18.2237
[12]	Pfeiffer, E. (1975) A short portable mental status questionnaire for the assessment of organic brain deficit in elderly patients. Journal of the American Geriatrics Society, 23, 433-441.
[13]	Folstein, M.F., Folstein, S.E. and McHugh, P.R. (1975) “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research, 12, 189-198. doi:10.1016/0022-3956(75)90026-6
[14]	Nasreddine, Z.S., Phillips, N. A., Bedirian, V., et al. (2005) The montreal cognitive assessment, moca: A brief screening tool for mild cognitive impairment. Journal of the American Geriatrics Society, 53, 695-699. doi:10.1111/j.1532-5415.2005.53221.x
[15]	Smith, T., Gildeh, N. and Holmes, C. (2007) The montreal cognitive assessment: Validity and utility in a memory clinic setting. Canadian Journal of Psychiatry, 52, 329-332.
[16]	Hoops, S., Nazem, S., Siderowf, A. D., et al. (2009) Validity of the MoCA and mmse in the detection of mci and dementia in parkinson disease. Neurology, 73, 1738-1745. doi:10.1212/WNL.0b013e3181c34b47
[17]	D'Agostino, R. B., Sr., Grundy, S., Sullivan, L. M. and Wilson, P. (2001) Validation of the framingham coronary heart disease prediction scores: Results of a multiple ethnic groups investigation. Journal of the American Medical Association, 286, 180-187. doi:10.1001/jama.286.2.180
[18]	D’Agostino, R.B., Wolf, P.A., Belanger, A.J. and Kannel, W.B. (1994) Stroke risk profile: Adjustment for antihypertensive medication. The framingham study. Stroke, 25, 40-43. doi:10.1161/01.STR.25.1.40
[19]	Victor, R. G., Haley, R. W., Willett, D. L., et al. (2004) The dallas heart study: A population-based probability sample for the multidisciplinary study of ethnic differences in cardiovascular health. American Journal of Cardiology, 93, 1473-1480.
[20]	Wilson, P.W., D’Agostino, R.B., Levy, D., et al. (1998) Prediction of coronary heart disease using risk factor categories. Circulation, 97, 1837-1847.
[21]	Aggarwal, A. and Kean, E. (2010) Comparison of the folstein mini mental state examination (mmse) to the montreal cognitive assessment (MoCA) as a cognitive screening tool in an inpatient rehabilitation setting. Neuroscience and Medicine, 1, 39-42. doi:10.4236/nm.2010.12006
[22]	Bernstein, I.H., Lacritz, L., Barlow, C.E., Weiner, M.F. and Defina, L. F. (2011) Psychometric evaluation of the montreal cognitive assessment (MoCA) in three diverse samples. Clinical Neuropsychology, 25, 119-126. doi:10.1080/13854046.2010.533196
[23]	McLennan, S.N., Mathias, J.L., Brennan, L.C. and Stewart, S. (2010) Validity of the montreal cognitive assessment (MoCA) as a screening test for mild cognitive impairment (MCI) in a cardiovascular population. Journal of Geriatric Psychiatry and Neurology, 24, 33-38.
[24]	Kuczynski, B., Jagust, W., Chui, H.C. and Reed, B. (2009) An inverse association of cardiovascular risk and frontal lobe glucose metabolism. Neurology, 72, 738-743. doi:10.1212/01.wnl.0000343005.35498.e5
[25]	Zade, D., Beiser, A., McGlinchey, R., et al. (2010) Interactive effects of apolipoprotein E type 4 genotype and cerebrovascular risk on neuropsychological performance and structural brain changes. Journal of Stroke and Cerebrovascular Diseases, 19, 261-268. doi:10.1016/j.jstrokecerebrovasdis.2009.05.001
[26]	Fillenbaum, G.G., Landerman, L.R., Blazer, D.G., et al. (2001) The relationship of APOE genotype to cognitive functioning in older African-American and caucasian community residents. Journal of the American Geriatrics Society, 49, 1148-1155. doi:10.1212/01.WNL.0000149643.91367.8A
[27]	Blair, C.K., Folsom, A.R., Knopman, D.S., et al. (2005) APOE genotype and cognitive decline in a middle-aged cohort. Neurology, 64, 268-276. doi:10.1212/01.WNL.0000149643.91367.8A
[28]	Wisdom, N.M., Callahan, J.L. and Hawkins, K.A. (2011) The effects of apolipoprotein e on non-impaired cognitive functioning: A meta-analysis. Neurobiology of Aging, 32, 63-74. doi:10.1001/jama.282.1.40
[29]	Haan, M.N., Shemanski, L., Jagust, W.J., Manolio, T.A. and Kuller, L. (1999) The role of APOE epsilon4 in modulating effects of other risk factors for cognitive decline in elderly persons. Journal of the American Medical Association, 282, 40-46. doi:10.1001/jama.282.1.40
[30]	Qiu, C. and Fratiglioni, L. (2010) Apolipoprotein E epsilon4 status and cognitive decline with and without dementia. Archives of Neurology, 67, 1036. doi:10.1001/archneurol.2010.163
[31]	Kozauer, N.A., Mielke, M.M., Chan, G.K., Rebok, G.W. and Lyketsos, C.G. (2008) Apolipoprotein e genotype and lifetime cognitive decline. International Psychogeriatrics, 20, 109-123. doi:10.1017/S104161020700587X